BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nielsen S, Needham B, Leach ST, Day AS, Jaffe A, Thomas T, Ooi CY. Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis. Sci Rep 2016;6:24857. [PMID: 27143104 DOI: 10.1038/srep24857] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Françoise A, Héry-Arnaud G. The Microbiome in Cystic Fibrosis Pulmonary Disease. Genes (Basel) 2020;11:E536. [PMID: 32403302 DOI: 10.3390/genes11050536] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
2 Lee AJ, Einarsson GG, Gilpin DF, Tunney MM. Multi-Omics Approaches: The Key to Improving Respiratory Health in People With Cystic Fibrosis? Front Pharmacol 2020;11:569821. [PMID: 33013411 DOI: 10.3389/fphar.2020.569821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Garg M, Leach ST, Pang T, Needham B, Coffey MJ, Katz T, Strachan R, Widger J, Field P, Belessis Y, Chuang S, Day AS, Jaffe A, Ooi CY. Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10years old.J Cyst Fibros. 2018;17:109-113. [PMID: 28754328 DOI: 10.1016/j.jcf.2017.07.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
4 Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742 [PMID: 34904041 DOI: 10.4254/wjh.v13.i11.1727] [Reference Citation Analysis]
5 Thavamani A, Salem I, Sferra TJ, Sankararaman S. Impact of Altered Gut Microbiota and Its Metabolites in Cystic Fibrosis. Metabolites 2021;11:123. [PMID: 33671639 DOI: 10.3390/metabo11020123] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kristensen MI, de Winter-de Groot KM, Berkers G, Chu MLJN, Arp K, Ghijsen S, Heijerman HGM, Arets HGM, Majoor CJ, Janssens HM, van der Meer R, Bogaert D, van der Ent CK. Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation. J Pers Med 2021;11:350. [PMID: 33925519 DOI: 10.3390/jpm11050350] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kristensen M, Prevaes SMPJ, Kalkman G, Tramper-Stranders GA, Hasrat R, de Winter-de Groot KM, Janssens HM, Tiddens HA, van Westreenen M, Sanders EAM, Arets B, Keijser B, van der Ent CK, Bogaert D. Development of the gut microbiota in early life: The impact of cystic fibrosis and antibiotic treatment. J Cyst Fibros 2020;19:553-61. [PMID: 32487494 DOI: 10.1016/j.jcf.2020.04.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
8 Vernocchi P, Del Chierico F, Russo A, Majo F, Rossitto M, Valerio M, Casadei L, La Storia A, De Filippis F, Rizzo C, Manetti C, Paci P, Ercolini D, Marini F, Fiscarelli EV, Dallapiccola B, Lucidi V, Miccheli A, Putignani L. Gut microbiota signatures in cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype. PLoS One. 2018;13:e0208171. [PMID: 30521551 DOI: 10.1371/journal.pone.0208171] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
9 Garg M, Ooi CY. The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy. Curr Gastroenterol Rep. 2017;19:6. [PMID: 28155088 DOI: 10.1007/s11894-017-0546-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
10 Wang Y, Leong LEX, Keating RL, Kanno T, Abell GCJ, Mobegi FM, Choo JM, Wesselingh SL, Mason AJ, Burr LD, Rogers GB. Opportunistic bacteria confer the ability to ferment prebiotic starch in the adult cystic fibrosis gut. Gut Microbes 2019;10:367-81. [PMID: 30359203 DOI: 10.1080/19490976.2018.1534512] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
11 Estaki M, Pither J, Baumeister P, Little JP, Gill SK, Ghosh S, Ahmadi-Vand Z, Marsden KR, Gibson DL. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomic functions. Microbiome. 2016;4:42. [PMID: 27502158 DOI: 10.1186/s40168-016-0189-7] [Cited by in Crossref: 156] [Cited by in F6Publishing: 144] [Article Influence: 26.0] [Reference Citation Analysis]
12 Ooi CY, Syed SA, Rossi L, Garg M, Needham B, Avolio J, Young K, Surette MG, Gonska T. Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation. Sci Rep. 2018;8:17834. [PMID: 30546102 DOI: 10.1038/s41598-018-36364-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
13 Coffey MJ, Garg M, Homaira N, Jaffe A, Ooi CY. A systematic cochrane review of probiotics for people with cystic fibrosis. Paediatr Respir Rev 2021;39:61-4. [PMID: 32917517 DOI: 10.1016/j.prrv.2020.06.020] [Reference Citation Analysis]
14 Karb DB, Cummings LC. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis. Curr Gastroenterol Rep 2021;23:17. [PMID: 34448955 DOI: 10.1007/s11894-021-00817-2] [Reference Citation Analysis]
15 Schepis T, De Lucia SS, Nista EC, Manilla V, Pignataro G, Ojetti V, Piccioni A, Gasbarrini A, Franceschi F, Candelli M. Microbiota in Pancreatic Diseases: A Review of the Literature. J Clin Med 2021;10:5920. [PMID: 34945216 DOI: 10.3390/jcm10245920] [Reference Citation Analysis]
16 Chilton AM, Neilan BA, Eldridge DJ. Biocrust morphology is linked to marked differences in microbial community composition. Plant Soil 2018;429:65-75. [DOI: 10.1007/s11104-017-3442-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 5.2] [Reference Citation Analysis]
17 Kanhere M, Chassaing B, Gewirtz AT, Tangpricha V. Role of vitamin D on gut microbiota in cystic fibrosis. J Steroid Biochem Mol Biol 2018;175:82-7. [PMID: 27818276 DOI: 10.1016/j.jsbmb.2016.11.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
18 Hoppe JE, Zemanick ET. Lessons from the lower airway microbiome in early CF. Thorax 2017;72:1063-4. [PMID: 28450530 DOI: 10.1136/thoraxjnl-2017-210060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
19 van Dorst JM, Tam RY, Ooi CY. What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics? Nutrients 2022;14:480. [DOI: 10.3390/nu14030480] [Reference Citation Analysis]
20 Meeker SM, Mears KS, Sangwan N, Brittnacher MJ, Weiss EJ, Treuting PM, Tolley N, Pope CE, Hager KR, Vo AT, Paik J, Frevert CW, Hayden HS, Hoffman LR, Miller SI, Hajjar AM. CFTR dysregulation drives active selection of the gut microbiome. PLoS Pathog 2020;16:e1008251. [PMID: 31961914 DOI: 10.1371/journal.ppat.1008251] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
21 Kan JM, Cowan CSM, Ooi CY, Kasparian NA. What can the gut microbiome teach us about the connections between child physical and mental health? A systematic review. Dev Psychobiol 2019;61:700-13. [DOI: 10.1002/dev.21819] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Le TN. Updates in vitamin D therapy in cystic fibrosis: . Current Opinion in Endocrinology & Diabetes and Obesity 2018;25:361-5. [DOI: 10.1097/med.0000000000000439] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Woo TE, Lim R, Heirali AA, Acosta N, Rabin HR, Mody CH, Somayaji R, Surette MG, Sibley CD, Storey DG, Parkins MD. A longitudinal characterization of the Non-Cystic Fibrosis Bronchiectasis airway microbiome. Sci Rep 2019;9:6871. [PMID: 31053725 DOI: 10.1038/s41598-019-42862-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
24 Enaud R, Prevel R, Ciarlo E, Beaufils F, Wieërs G, Guery B, Delhaes L. The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks. Front Cell Infect Microbiol 2020;10:9. [PMID: 32140452 DOI: 10.3389/fcimb.2020.00009] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 41.0] [Reference Citation Analysis]
25 Coffey MJ, Garg M, Homaira N, Jaffe A, Ooi CY. Probiotics for people with cystic fibrosis. Cochrane Database Syst Rev 2020;1:CD012949. [PMID: 31962375 DOI: 10.1002/14651858.CD012949.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
26 Shukla SD, Budden KF, Neal R, Hansbro PM. Microbiome effects on immunity, health and disease in the lung. Clin Transl Immunology 2017;6:e133. [PMID: 28435675 DOI: 10.1038/cti.2017.6] [Cited by in Crossref: 120] [Cited by in F6Publishing: 108] [Article Influence: 24.0] [Reference Citation Analysis]
27 Garg M, Leach ST, Coffey MJ, Katz T, Strachan R, Pang T, Needham B, Lui K, Ali F, Day AS, Appleton L, Moeeni V, Jaffe A, Ooi CY. Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children. J Cyst Fibros 2017;16:631-6. [PMID: 28416415 DOI: 10.1016/j.jcf.2017.03.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
28 Marsh R, Gavillet H, Hanson L, Ng C, Mitchell-Whyte M, Major G, Smyth AR, Rivett D, van der Gast C. Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)02155-X. [PMID: 34895838 DOI: 10.1016/j.jcf.2021.11.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Quin C, Vollman DM, Ghosh S, Haskey N, Estaki M, Pither J, Barnett JA, Jay MN, Birnie BW, Gibson DL. Fish oil supplementation reduces maternal defensive inflammation and predicts a gut bacteriome with reduced immune priming capacity in infants. ISME J 2020;14:2090-104. [PMID: 32398661 DOI: 10.1038/s41396-020-0672-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Eng A, Hayden HS, Pope CE, Brittnacher MJ, Vo AT, Weiss EJ, Hager KR, Leung DH, Heltshe SL, Raftery D, Miller SI, Hoffman LR, Borenstein E. Infants with cystic fibrosis have altered fecal functional capacities with potential clinical and metabolic consequences. BMC Microbiol 2021;21:247. [PMID: 34525965 DOI: 10.1186/s12866-021-02305-z] [Reference Citation Analysis]
31 Konrad J, Eber E, Stadlbauer V. Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators. Paediatr Respir Rev 2020:S1526-0542(20)30181-0. [PMID: 33485777 DOI: 10.1016/j.prrv.2020.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Coffey MJ, Low I, Stelzer-Braid S, Wemheuer B, Garg M, Thomas T, Jaffe A, Rawlinson WD, Ooi CY. The intestinal virome in children with cystic fibrosis differs from healthy controls. PLoS One 2020;15:e0233557. [PMID: 32442222 DOI: 10.1371/journal.pone.0233557] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
33 Willis JR, Saus E, Iraola-Guzmán S, Cabello-Yeves E, Ksiezopolska E, Cozzuto L, Bejarano LA, Andreu-Somavilla N, Alloza-Trabado M, Blanco A, Puig-Sola A, Broglio E, Carolis C, Ponomarenko J, Hecht J, Gabaldón T. Citizen-science based study of the oral microbiome in Cystic fibrosis and matched controls reveals major differences in diversity and abundance of bacterial and fungal species. J Oral Microbiol 2021;13:1897328. [PMID: 34104346 DOI: 10.1080/20002297.2021.1897328] [Reference Citation Analysis]
34 Zhang D, Li S, Wang N, Tan HY, Zhang Z, Feng Y. The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases. Front Microbiol 2020;11:301. [PMID: 32158441 DOI: 10.3389/fmicb.2020.00301] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 33.0] [Reference Citation Analysis]
35 Burke DG, Fouhy F, Harrison MJ, Rea MC, Cotter PD, O'Sullivan O, Stanton C, Hill C, Shanahan F, Plant BJ, Ross RP. The altered gut microbiota in adults with cystic fibrosis. BMC Microbiol. 2017;17:58. [PMID: 28279152 DOI: 10.1186/s12866-017-0968-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
36 Acosta N, Heirali A, Somayaji R, Surette MG, Workentine ML, Sibley CD, Rabin HR, Parkins MD. Sputum microbiota is predictive of long-term clinical outcomes in young adults with cystic fibrosis. Thorax 2018;73:1016-25. [PMID: 30135091 DOI: 10.1136/thoraxjnl-2018-211510] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
37 Acosta N, Whelan FJ, Somayaji R, Poonja A, Surette MG, Rabin HR, Parkins MD. The Evolving Cystic Fibrosis Microbiome: A Comparative Cohort Study Spanning 16 Years. Ann Am Thorac Soc 2017;14:1288-97. [PMID: 28541746 DOI: 10.1513/AnnalsATS.201609-668OC] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
38 Coffey MJ, Nielsen S, Wemheuer B, Kaakoush NO, Garg M, Needham B, Pickford R, Jaffe A, Thomas T, Ooi CY. Gut Microbiota in Children With Cystic Fibrosis: A Taxonomic and Functional Dysbiosis. Sci Rep 2019;9:18593. [PMID: 31819107 DOI: 10.1038/s41598-019-55028-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
39 Bass R, Brownell JN, Stallings VA. The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status. Nutrients 2021;13:2907. [PMID: 34578785 DOI: 10.3390/nu13092907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Enaud R, Hooks KB, Barre A, Barnetche T, Hubert C, Massot M, Bazin T, Clouzeau H, Bui S, Fayon M, Berger P, Lehours P, Bébéar C, Nikolski M, Lamireau T, Delhaes L, Schaeverbeke T. Intestinal Inflammation in Children with Cystic Fibrosis Is Associated with Crohn's-Like Microbiota Disturbances. J Clin Med 2019;8:E645. [PMID: 31083321 DOI: 10.3390/jcm8050645] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
41 Coffey MJ, Garg M, Homaira N, Jaffe A, Ooi CY; Cochrane Cystic Fibrosis and Genetic Disorders Group. Probiotics for people with cystic fibrosis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012949] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Dorsey J, Gonska T. Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine. J Cyst Fibros 2017;16 Suppl 2:S14-23. [PMID: 28986022 DOI: 10.1016/j.jcf.2017.07.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 8.8] [Reference Citation Analysis]
43 Coffey MJ, McKay IR, Doumit M, Chuang S, Adams S, Stelzer-Braid S, Waters SA, Kasparian NA, Thomas T, Jaffe A, Katz T, Ooi CY. Evaluating the Alimentary and Respiratory Tracts in Health and disease (EARTH) research programme: a protocol for prospective, longitudinal, controlled, observational studies in children with chronic disease at an Australian tertiary paediatric hospital. BMJ Open 2020;10:e033916. [PMID: 32295774 DOI: 10.1136/bmjopen-2019-033916] [Reference Citation Analysis]
44 Hardouin P, Chiron R, Marchandin H, Armengaud J, Grenga L. Metaproteomics to Decipher CF Host-Microbiota Interactions: Overview, Challenges and Future Perspectives. Genes (Basel) 2021;12:892. [PMID: 34207804 DOI: 10.3390/genes12060892] [Reference Citation Analysis]